Cartography Biosciences is an early-stage precision immunotherapy company building a comprehensive antigen “atlas” and a pipeline of antibody‑based and multispecific cancer therapies designed to find safer, tumor‑specific targets and advance them into the clinic[4][5].
High-Level Overview
- Mission: Develop next‑generation targeted cancer therapies by identifying cancer‑specific antigens at single‑cell scale and using those insights to create safer, more effective immunotherapies[4][2].[4]
- Investment philosophy (for context — Cartography as a portfolio company): Cartography is backed by investors such as 8VC and completed a major Series B financing in October 2025, raising approximately $67M to advance its differentiated oncology pipeline into the clinic[2][3][4].[3]
- Key sectors: Precision oncology, immuno‑oncology, single‑cell genomics and proteomics, antibody engineering and multispecific biologics[4][5].[4]
- Impact on the startup ecosystem: By combining high‑throughput single‑cell antigen profiling with binder discovery and therapeutic development, Cartography both accelerates target discovery workflows and raises the bar for translational single‑cell platforms in biotech, encouraging partnerships between genomics, computational biology, and antibody engineering groups[4][1].[4]
As a portfolio company, Cartography builds an antigen atlas and antibody‑based therapeutics that serve biopharma R&D and ultimately cancer patients and clinicians; it addresses the critical problem of finding targets that are expressed on tumors but not on vital normal tissues, aiming to improve safety and broaden the set of treatable cancers[4][5].[5] The company has public pipeline programs (e.g., multispecific antibodies and T‑cell engagers) and announced Series B funding and strategic collaborations to support clinical advancement, indicating notable growth momentum into late preclinical/early clinical stages in 2024–2025[3][4][5].[3]
Origin Story
- Founding and team: Cartography was founded around 2022 by leaders including Kevin Parker, Howard Chang, and Ansu Satpathy, building on work from major genomics labs and launching with initial investor support to advance a therapeutics pipeline informed by single‑cell biology[1][4].[1]
- How the idea emerged: The company’s genesis is rooted in translating high‑resolution single‑cell genomics and proteomics—profiling antigen expression cell‑by‑cell across healthy and tumor tissues—into a systematic atlas that guides target selection for antibody‑based modalities[4].[4]
- Early traction / pivotal moments: Early traction includes formation of a discovery platform (ATLAS) for antigen characterization, public disclosure of multiple discovery programs and therapeutic formats on its pipeline page, strategic collaborations (including a notable collaboration with Gilead), leadership hires such as a Chief Medical Officer, and a $67M Series B in October 2025 to push programs toward the clinic[4][5][3].[4]
Core Differentiators
- Platform + data depth: A purpose‑built antigen ATLAS combining single‑cell genomics and proteomics across thousands of patient samples to map antigen expression with tissue‑level context—enabling assessment of tumor specificity and normal‑tissue risk at scale[4].[4]
- Target‑first approach: Prioritizes antigen expression patterns (rather than histology or single mutations) to identify targets that are both tumor‑restricted and broadly represented across a patient’s tumor cells[4].[4]
- Multimodal therapeutic engineering: Focus on antibody‑based modalities including bispecifics, T‑cell engagers, ADCs, and novel geometries (1+1, 2+1, tri‑epitopic formats) supported by internal binder discovery and optimization capabilities[1][5].[1]
- Binder discovery & optimization: In‑house capabilities spanning phage/yeast display, computational design, affinity maturation and biophysical characterization to convert atlas hits into therapeutic candidates[1][6].[1]
- Strategic partnerships & capital: Backing from investors (e.g., 8VC) and collaborations with larger biopharma players to accelerate translational and clinical steps[2][4].[2]
Role in the Broader Tech & Biotech Landscape
- Trend alignment: Cartography rides two converging trends—single‑cell multiomic profiling and computational target discovery—applied directly to the unmet need of identifying safer immuno‑oncology targets[4].[4]
- Timing: Advances in single‑cell assay throughput and antigen detection, plus growing demand for multispecific and precision biologics to reduce on‑target/off‑tumor toxicity, create a favorable window for an atlas‑driven target identification company[4][5].[4]
- Market forces: Pharmaceutical interest in novel, safer oncology targets and the commercial potential of differentiated immunotherapies (bispecifics, TCEs, ADCs) support investment and partner appetite for platforms that de‑risk target selection[3][5].[3]
- Ecosystem influence: By demonstrating a data‑centric path from target discovery to therapeutic engineering, Cartography may accelerate similar vertical integrations in biotech and encourage more collaborations between single‑cell technology providers and therapeutic developers[4][1].[4]
Quick Take & Future Outlook
- Near term (12–24 months): Expect clinical translations of lead programs or IND‑enabling workstream advancement supported by Series B capital, plus expansion of the ATLAS dataset and additional partner deals or licensing opportunities as targets mature[3][5].[3]
- Mid term (2–5 years): If clinical safety and early efficacy readouts are positive, Cartography could validate the antigen‑atlas model, enabling faster selection of safer targets and positioning the company either as a mid‑stage clinical biotech or as an attractive acquisition partner for larger oncology players[4][5].[4]
- Risks and shaping trends: Key risks include the translational uncertainty inherent to novel oncology targets and the challenge of demonstrating clear safety advantages versus incumbent approaches; success will hinge on robust atlas validation, binder performance, and clinical outcomes[4][5].[4]
- Strategic implications: Positive clinical proof‑points would strengthen the case for atlas‑led drug discovery as a repeatable, platform‑level advantage—potentially changing how immuno‑oncology targets are prioritized across the industry[4][2].[4]
Quick take: Cartography blends deep single‑cell antigen mapping with in‑house binder and antibody engineering to attack a central bottleneck in immuno‑oncology—safe, tumor‑specific target discovery—and recent Series B funding plus industry collaborations position it to test that thesis in the clinic over the coming years[4][3][5].[4]
If you’d like, I can: (a) summarize their public pipeline and program modalities in a compact table, (b) pull timelines for specific programs/INDs from clinicaltrials.gov, or (c) map their investor and partnership network in more detail.
